Navigation Links
USAID awards CONRAD and Eastern Virginia Medical School funding for development of new HIV prevention

Norfolk, Va. Richard V. Homan, MD, President and Provost of Eastern Virginia Medical School (EVMS) and Dean of the School of Medicine, along with Alfred Z. Abuhamad, Chair and Professor of EVMS Obstetrics and Gynecology, announced today that CONRAD, a leading reproductive health-research organization at the school, will receive up to $80 million over the course of five years from the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID). The awards will fund three areas of HIV prevention research including: licensure and implementation of tenofovir gel, development of novel on-demand and longer-acting microbicide leads, and development of objective measures of product adherence for vaginal and rectal microbicides.

Globally, 35.3 million people are currently infected with HIV, and in South Africa, prevalence of HIV has increased from 10.6% in 2008 to 12.3% in 2012. Young, single women account for the highest rate of new infections, and condom use in South Africa has fallen in all age groups. The need to develop and implement prevention options for those at highest risk of infection continues to be a top public health research priority. The U.S. Congress recently approved legislation to extend PEPFAR, a foreign aid program to combat AIDS worldwide.

CONRAD Scientific and Executive Director Gustavo Doncel, M.D., Ph.D. said, "We are deeply grateful to USAID for their continued support, and to PEPFAR and the U.S. Congress for making HIV prevention a priority. These awards coincide with World AIDS Day and reflect the unwavering commitment of the American people to support the fight against the AIDS epidemic worldwide. The funds will support multi-faceted research and allow us to advance and develop a variety of prevention products which include on-demand and long-lasting options for different women's needs. We plan to incorporate input on user preferences early in the product development process and develop objective measures of adherence to enable a more accurate evaluation of the new microbicides. Developing products that women want to use as opposed to have to use is key to the successful assessment and implementation of HIV prevention strategies, especially in young women who are most at risk for HIV infection."

Tenofovir gel was the first product to provide proof of concept that a vaginal gel used before and after sex could reduce HIV-1 and HSV-2 infections. A confirmatory study of tenofovir gel called FACTS 001, sponsored by CONRAD and funded by USAID, the South African government and the Bill and Melinda Gates Foundation, is currently ongoing and if the results again show protection, the gel has been fast tracked by the FDA for regulatory approval.

Other products in CONRAD's pipeline include a fast-disintegrating vaginal tablet and two vaginal rings that have the potential to be effective for up to three months. One ring in testing contains tenofovir plus a contraceptive called levonorgestrel, a combination that has the potential to provide triple protection against unintended pregnancies and HIV and herpes. Safety, pharmacokinetic and pharmacodynamic studies will begin in 2014.

Using this funding, CONRAD will continue development of new microbicide products that are more potent, acceptable, discreet, and longer acting to improve adherence and effectiveness. In addition to advancing clinical development of the current pipeline, CONRAD also will explore new formulations consisting of antiretrovirals displaying different mechanisms of action.

Adherence, or regular and consistent use of a product, has been shown to be problematic in various HIV prevention trials. Adherence is conditioned by socio-behavioral, biologic and environmental factors and without consistent use, it is extremely difficult for researchers to gauge true product effectiveness. In light of this, CONRAD will continue development and validation of biomarkers for measuring adherence and its possible use in alternative trial designs.

"We are very proud to continue supporting CONRAD's excellent work," said USAID Program Officer Lee Claypool, PhD. "Together with our partners in the private sector and participating African governments, I'm very optimistic that we will continue to forge new ground in HIV prevention."


Contact: Annette Larkin

Related medicine news :

1. First anti-tuberculosis medicine under USAID-supported PQM program achieves WHO prequalification
2. URC receives USAIDs Excellence in Mentorship Award
3. USD $1.15 Billion Commitment over Three Years to Help Save the Lives of Children and Women Secured through World Bank, UNICEF, USAID and Norway
4. URC leads new USAID project to improve Haitis health care system
5. IPM receives 2 awards from USAID to advance HIV prevention technologies for women
6. Population Council awarded flagship family planning implementation science project by USAID
7. NIH awards $20 million over 5 years to train next generation of global health researchers
8. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
9. Washingtons Life Sciences Discovery Fund awards commercialization grants
10. Awards celebrate clinical research that can improve health and alleviate suffering
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
Related Image:
USAID awards CONRAD and Eastern Virginia Medical School funding for development of new HIV prevention
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced that Dr. Christine Milligan, Global ... Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy ... , FDA has long asserted that design and manufacture of Laboratory Developed ... and do not meet the device regulations. , Come up short in an inspection ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Bolier Reactor System. Brillouin is the developer of renewable energy technologies capable of ... nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, Inc ... less-invasive, miniaturized circulatory support technologies that are revolutionizing the ... and Chief Executive Officer Doug Godshall is ... Annual Healthcare Conference on December 1, 2015 at ... 1-2 in New York . ...
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... iRhythm Technologies, Inc. , a leading digital health care solutions ... participate in the 27th Annual Piper Jaffray Healthcare Conference at The ... . Kevin King , Chief Executive Officer of iRhythm, ... ET. --> --> About ... . --> iRhythm is a privately held digital ...
Breaking Medicine Technology: